LipoCore hints at major partner

LipoCore's drug delivery technology is to be the subject of a major feasibility study at one of the largest multinational pharmaceutical manufacturers in the autumn, according to the company.

The Swedish company​ has developed a delivery system based on galactolipids, derived from cereals, that is claimed to improve the solubility of drugs without affecting their activity. The system, developed under the Galacticle banner, is suitable for use in delivering oral, parenteral, topical and ophthalmic medicines and improves solubility, offers good emulsification properties and can spontaneously form liposomes.

Galacticles' emulsifying profile means that there is less variability between fed and fasting states in the absorption of the active substance, so there should be fewer restrictions on dosing and administration.

The feasibility study is a step up for LipoCore, which until now has been contracted to apply its technologies to pharma and biotech company projects on a smaller scale.

LipoCore has also developed a depot formulation technology, Cerelease, based on ceramides that can allow long-term release of an active drug over several months.